{
  "messages": [
    {
      "role": "system",
      "content": "You are a medical tutor that helps users digest complex medical research papers. You create study guides and offer advice to help the user study the concept(s) described in a given paper. Study guides should start by including a global summary of the paper in about 200 words. Then, provide a bulleted list of key concepts. Then, provide multiple choice questions to quiz the user. You should end the response with a suggestion for another reading on the topic. Further reading: Provide 1\u20132 high-quality suggestions (landmark trials, guidelines, or systematic reviews). Include full citation details and DOI when available.\nBe friendly, encouraging, but technical and high-level in your responses. Target users are medical school students, pharmacy students, DO students, and other health professional students and residents. Include a brief disclaimer at the end \"For learning purposes only; not medical advice.\"\nIf only an abstract is available, proceed but clearly label limitations due to incomplete data.\nFormatting: Use clear section headers in this order\u2014Global Summary; Key Concepts; Quiz; Answer Key and Rationales; Suggested Further Reading. Use concise bullets; number MCQs; label options A\u2013E. Keep a professional, high-level tone."
    },
    {
      "role": "user",
      "content": "1050 Journal of the American College of Clinical Pharmacy, 2025Study Study designNumber ofpatients orculturesParticipantsassessedDisciplinesinvolved in culturereview processPositive/negativeculturesreviewedTypes of cultures/tests reviewedClinical and/or time-basedoutcomes (pharmacistvs. no pharmacist unlessotherwise indicated)Davis 2016[8]Pre-post 72 patient visits Adults EM Pharmacist; MD Positivecultures onlyBlood cultures; Urinecultures; Wound; StoolAverage days to intervention (SD):3.5 (1.2) vs. 3.4 (1.9), p = 0.81Zhang 2017[9]Prospectiveobservationalcohort, non-comparative136 patients Adults RN; Midlevel; EMPharmacistPositivecultures onlyUrine cultures n/aWaters 2017[10]Pre-post 245 patients Unspecified EM Pharmacist;Provider (typenot specified)Positivecultures onlyBlood cultures 90-day attributable admission/readmission: 2.9% vs. 12.1%,P = 0.01; 90-day attributablemortality: 1% vs. 1%, p = 0.8337Grill 2019[11]Prospective,observational,exploratorydescriptive,non-comparativen/a Unspecified EM Pharmacist (CPA) Not specified Blood cultures; Urinecultures; Othern/aAlmulhim2019 [12]Pre-post 157 patients Adults Pharmacist (anyspecialty)Positivecultures onlyUrine cultures n/aWu 2020 [13] Retrospective,observational,non-comparative9107microbiologyresults and6211 laboratoryresultsAdults;PediatricsEM Pharmacist;Provider (typenot specified); IDpharmacistsPositivecultures onlyBlood cultures;Urine cultures; STI;Wound; Respiratory;Stool; ThroatMedian time to review and completelaboratory results: 3.6 h [IQR 0.5\u201314.5]; Time to review and completemicrobiology Results: 25.3 h (9.0\u201343.8)Tweedle2020 [14]Pre-post 852 cultures Pediatrics EM Pharmacist;Provider (typenot specified)Positivecultures onlyUrine cultures; Genital Interventions within 12 h: 5.4%vs. 1.8%, p = 0.011; Mean times ofnotification for genital cultures:21.7 h versus 22.8 h, p = 0.762; Urinecultures: 46.4 h vs. 67.4 h, p = 0.354(Continues)TABLE 1 | (Continued)1051Study Study designNumber ofpatients orculturesParticipantsassessedDisciplinesinvolved in culturereview processPositive/negativeculturesreviewedTypes of cultures/tests reviewedClinical and/or time-basedoutcomes (pharmacistvs. no pharmacist unlessotherwise indicated)Shealy 2020[15]Pre-post 127 patients Adults Pharmacy resident;EM Pharmacist; MDPositivecultures onlyBlood cultures;urine cultures; STI;Wound; StoolED revisit within 30 days: 19.1%versus 15.6%, p = 0.783; ED revisitrelated to index case: 0% versus 7.3%;Hospital admission within 30 days7.9% versus 9.4%, p = 1.0 Average timeto first attempted patient contact:62.3 h versus 79.7 h, p = 0.005Average time to initial review:47.9 h vs. 75.2 h, p < 0.001Average to intervention complete:89.4 h versus 110.7 h, p = 0.114Roels 2020[16]Retrospectiveobservational,non-comparative1589 cultures Adults;PediatricsEM Pharmacist(CPA); Provider (typenot specified)Positivecultures onlyBlood cultures; Urinecultures; STI; Wound/abscess, Streptococcalpharyngitisn/aOlson 2020[17]Pre-post 283 patients Adults EM Pharmacist;Provider (typenot specified)Positivecultures onlyUrine cultures; STI Treatment failure: 0.01% versus 6.3%,P = 0.01; Hospital admission within30 days: 0% vs. 4.2%, p = 0.03 Mediantime to patient contact: 9.06 h [21.92\u20132.6] vs. 26.47 h [50.15\u201321.68], P < 0.001Loborec2020 [18]Pre-post(beforeand afterprivilegingpharmacists)178 test results Adults Pharmacy resident;ED specialty practicepharmacist, privilegedPositivecultures onlyBlood cultures; Urinecultures; STI; Viralpanels; Soft tissueMedian time to patient contact:14.9 h [2.5\u201327.9] vs. 23.6 h[12.4\u201393], P = 0.0023Giruzzi 2020[19]Pre-post 790 patients Adults Midlevel (CRNP,PA); Pharmacist(any specialty); MD;Assistant ED directorPositivecultures onlyBlood cultures; Urinecultures; Wound; Other30-day ED return visit or hospitaladmission: n = 43 vs. n = 36, p = 0.367Median time to initial review:0.32 days [0.076\u20131.12] vs. 9.83[2.34\u201313.21] days, P < 0.001 Mediantime to modification of antibiotictherapy: 1.99 days [IQR 0.34\u20133.41]vs. 6.79 days [1.09\u20139.38], p < 0.001(Continues)TABLE 1 | (Continued)1052 Journal of the American College of Clinical Pharmacy, 2025Study Study designNumber ofpatients orculturesParticipantsassessedDisciplinesinvolved in culturereview processPositive/negativeculturesreviewedTypes of cultures/tests reviewedClinical and/or time-basedoutcomes (pharmacistvs. no pharmacist unlessotherwise indicated)Rainess 2021[20]Pre-post 311 patients Adults Midlevel; Pharmacist(any specialty)Positivecultures onlyUrine cultures; SSTI ED revisit within 30 days: 2.20%versus 5.45%, p = 0.209Campo 2021[21]Retrospectiveobservational,non-comparative490 patients Adults;PediatricsPharmacy resident;Pharmacist (anyspecialty) (CPA)Positivecultures onlyBlood cultures; Urinecultures; STI; Wound;Viral; C. difficile; Fungaln/aDietrich2022 [22]Retrospectiveobservational,non-comparative10 894 EDoutpatientculture reviewinterventionsUnspecified EM Pharmacist(CPA); MDNot specified Blood cultures; Urinecultures; STI; Tissue;Abscess; Throat,Viral panelsn/aCornell 2022[23]Pre-post 200interventionsAdults;PediatricsMD; ClinicalPharmacistPractitioner (CPP)Positivecultures onlyUrine cultures; STI;Tissue; StreptococcalpharyngitisMedian time from culture resultto initial review: 1.67 h vs. 4.84 h(P < 0.001) Median time from initialculture review to documentedintervention, pharmacist versus nopharmacist: 2.95 h vs. 5.27 h (p < 0.001)Median time for entire cultureresponse process, pharmacist versus nopharmacist: 7.47 h vs. 19.48 h (p < 0.001)Zhao 2023[24]Pre-post 142 patients Adults;PediatricsRN; EM Pharmacist;Provider (typenot specified)Positivecultures onlyUrine cultures ED revisit directly related to indexvisit at 14 days: 7% versus 7%,p = 0.963; at 30 days\u201410% vs. 14%,p = 0.402; Hospital admission at30 days\u20140% versus 1%, p = 0.493Pham 2023[25]Pre-post 265 culturesfrom 264patientsAdults ED pharmacists,privilegedPositivecultures onlyUrine cultures 30-day ED revisit: 2.3% vs. 8.5%,p = 0.08 Median time from result toprogress note charted: 7 h [2.3\u201315.7]versus 14.5 h [2.7\u201325.7], p = 0.54Kofoed 2023[26]Pre-post 61 patients Adults Pharmacy resident;Provider (typenot specified)Negativecultures onlyUrine cultures ED return visit within 30 days:17% vs. 16%, P = 1.0(Continues)TABLE 1 | (Continued)1053Study Study designNumber ofpatients orculturesParticipantsassessedDisciplinesinvolved in culturereview processPositive/negativeculturesreviewedTypes of cultures/tests reviewedClinical and/or time-basedoutcomes (pharmacistvs. no pharmacist unlessotherwise indicated)Brenneman2023 [27]Retrospectiveobservationalstudy withpharmacistson-duty versusoff-duty71 patients Adults RN; Pharmacy resident;EM Pharmacist; MDPositivecultures onlyBlood cultures 30-day readmission rates, pharmaciston duty vs. off duty: 7.4% versus 5.9%,p = 0.95Median from culture resultto initial review: 0.8 h [IQR 0.4\u20132.8]versus 5.6 h [IQR 1.4\u201311.7], p = 0.025Benson 2023[28]Pre-post 234 urineculturesUnspecified Pharmacist (anyspecialty); Provider(type not specified)Positive andnegativeculturesUrine cultures n/aBao 2023[29]Retrospectiveobservational,non-comparative1088 patients Adults;PediatricsMidlevel (CRNP, PA);Other: Antimicrobialstewardship pharmacistPositivecultures onlyBlood cultures; Urinecultures; PCR-basedblood; Othern/aAndrade2023 [30]Pre-post 130 patients Adults Pharmacy resident;EM Pharmacist (CPA);Other: microbiologylaboratoryPositivecultures onlyBlood cultures; Urinecultures; STI; WoundED revisit within 30 days: 12.9%versus 28.3%, p = 0.046Wang 2024[31]Pre-post(before andafter expandedculturecallbackprotocol)192 patients Adults Pharmacy resident;EM Pharmacist; MDNegativecultures onlyUrine cultures; STI n/aRichardson2024 [32]Pre-post 141 patients Adults Pharmacy resident;Pharmacist (anyspecialty); EMPharmacist; Provider(type not specified);ED secretaryPositivecultures onlyBlood cultures; Urinecultures; Tissue;Throat; StoolED revisits within 7 days: 7% versus17%, p = 0.0454 Hospitalizationswithin 30 days for same condition:1% versus 8%, p = 0.0137Boot 2024[33]Pre-post 200 cultures Adults Pharmacist (anyspecialty); Provider(type not specified)Positivecultures onlyBlood cultures; Urinecultures; STIED revisit within 30 days: 7% versus8%, p = 0.788Admitted within 30 days:2% versus 4%, p = 0.407 Average timeto culture review: 27.6 h versus 29.1 hAbbreviations: CPA = collaborative practice agreement; CPP = clinical pharmacist practitioner; CRNP = certified registered nurse practitioner; CSF = cerebrospinal fluid; ED = emergency department; EM = emergency medicine;h = hour; ID = infectious disease; IQR = interquartile range; MD = doctor of medicine; n/a = not applicable; PA = physician's assistant; PCR = polymerase chain reaction; RN = registered nurse; SD = standard deviation; SSTI = skinand soft tissue infection; STI = sexually transmitted infection.TABLE 1 | (Continued)1054 Journal of the American College of Clinical Pharmacy, 20253.1 | Clinical Outcomes3.1.1 | Rate of ED Revisit or Hospital ReadmissionSixteen studies evaluated ED revisit rates and hospital re-admission end points ranging from 72 h to 90 days (Table 1).Across all studies detailing clinical outcomes, ED revisit and/or readmission rates ranged from 0% to 19.1% in the pharma-cist arms and from 4.2% to 28.3% in the control arms. Onlysome of the ED revisit and readmission end points assessedwithin the studies were directly attributable to the initial pre-senting condition [10, 11, 15\u201317]. Two studies evaluated therate of ED revisit or hospital readmission within 96 h [11, 18].Pharmacist intervention had mixed results in reducing thisoutcome, with Randolph and colleagues demonstrating a 12%reduction in readmission/ED revisit rates, while Santiago andcolleagues showed no difference [11, 18]. A combined rate ofED revisits within 72 h or hospital admissions within 30 dayswas assessed by one study and had a significant reductionwith pharmacist involvement in the subset of patients withoutmedical insurance [1].Ten studies examined ED revisit rates, specifically, one at7 days [16] and nine at 30 days [10, 15, 19\u201325]. ED revisit rateswere reduced in three studies by 4.2% to 15.4% with pharma-cist involvement [16, 19, 21] while others showed no signifi-cant difference [15, 20, 22\u201325]. Shealy and colleagues found areduction in ED revisit rates when examining those directlyrelated to the index case; however, the small sample size lim-ited the ability to conduct meaningful statistical analysis forthis outcome [10].3.1.2 | Appropriateness of Interventionsand Antimicrobial RegimensA few studies assessed whether pharmacist involvement inED culture follow-up services increased the number of ap-propriate interventions. The definition of \u201cappropriate inter-ventions\u201d varied across studies. Brenneman and colleaguescompared blood cultures resulting when an ED pharmacistwas on- duty versus off- duty [26]. They considered adherenceto a local algorithm for patient contact and follow-up as thestandard, with an infectious disease (ID) physician reviewingany deviation from the algorithm. Two recommendations inthe off- duty group were deemed incorrect, while no recom-mendations in the on- duty group were incorrect [26]. Loborecand colleagues assessed rates of erroneous interventions be-fore and after pharmacist privileging [9]. They categorizedinterventions as erroneous if they were incorrect (e.g., wors-ening coverage), missed (e.g., failure to adjust inadequatetherapy), or unnecessary (e.g., modifying already adequatetherapy), also with review by an ID physician. They foundthat prior to implementing pharmacist privileging, 1.1% ofreviewed test results were erroneous compared with 2.3%after implementing pharmacist privileging. Almulhim andcolleagues reviewed pharmacist-led versus NP-led culture fol-low-up interventions [27]. They defined inappropriate inter-ventions as inappropriately treated asymptomatic bacteriuria,inappropriate frequency or choice based on indication, or lackof follow-up call upon negative or mixed flora urine culture.Among patients requiring an intervention, 86% were deemedappropriate in the pharmacist group compared with 41% inthe NP group, largely driven by treatment of asymptomaticbacteriuria.Several studies consistently demonstrated improved inter-vention rates with pharmacist involvement. Brenneman andcolleagues showed that cultures were more frequently re-viewed when pharmacists were on duty (98.1%) versus off-duty (76.5%) [26]. One study reported a higher rate of cultureswith intervention when a pharmacist was involved (40.4%)compared to without (27.5%) (p < 0.001) [28]. Santiago andcolleagues and Davis and colleagues both found significantlyfewer missed interventions in pharmacist- driven models com-pared with nurse- driven ones, with missed intervention ratesof 4% versus 47% (p = 0.0004) and 20% versus 50% (p = 0.01),respectively [1, 18].Pharmacist involvement was associated with increased ratesof appropriate antimicrobial regimens in several studies butno difference in others, with studies using varying definitionsfor \u201cappropriate antimicrobial therapy.\u201d Miller and colleaguesestablished five levels of inappropriate antibiotic prescrip-tions, ranging from Level 1 (incorrect revised antimicrobialbased on susceptibility) to Level 5 (revised antimicrobial reg-imen conflicts with allergy history) [29]. Two investigatorsevaluated appropriateness independently, and an ED physi-cian adjudicated determinations when necessary. A study byMiller and colleagues demonstrated that culture callbacksrequired less revision of inappropriate regimens with phar-macist participation than without (14.7% vs. 46.6%, p < 0.001)[29]. The authors noted that the greatest differences werewith respect to antimicrobial choice, treatment duration, anddose adjustments for underlying renal or liver disease. Bootand colleagues assessed rates of optimal therapy (defined asa composite of optimal drug, dose, frequency, and duration)based on national and institutional guidelines and consider-ing patient- specific factors and appropriate therapy (definedas antibiotic that would cover the organisms but not deemedoptimal therapy) [22]. Combined optimal and appropriate ther-apy was higher in the pharmacist-led culture follow-up groupcompared with the nursing-led group (78% vs. 60%, p = 0.006).Waters and colleagues assessed pharmacist versus physician-managed cohorts of patients with bacteremia, with appro-priateness decided on with input from an infectious diseasephysician and based on national guidelines and best practicerecommendations [17]. Appropriate treatment increased in thepharmacist-managed cohort (47% vs. 95%, p < 0.0001). Bakerand colleagues defined inappropriate therapy as occurringif the antibiotic would not treat the presumed/documentedpathogen, was inconsistent with guideline recommendations,or based on local antibiogram data [8]. They found no differ-ence in appropriate antimicrobial therapy with and withoutED pharmacist involvement. Cornell and colleagues definedappropriate antibiotic selection based on susceptible inter-pretive criteria, with no differences between a nurse- drivenprogram versus an advanced practice pharmacist- driven pro-gram [28].A few studies looked at adherence to guideline- directedtherapy or optimal therapy\u2014all showed increases with1055pharmacist involvement [15, 17, 20, 22, 25]. Kofoed and col-leagues and Benson and colleagues both demonstrated a sig-nificant increase in appropriate discontinuation of therapy bypharmacists (40% vs. 0%, p < 0.001; 14.7% vs. 0%, p < 0.001),respectively [24, 30]. Rainess and colleagues and Zhang andcolleagues found reductions in the number of antibiotic dayswith pharmacist intervention, ranging from 122 to 280 days[25, 31].3.1.3 | Treatment Failure and MortalityOlson and colleagues demonstrated that pharmacist interven-tion was associated with less than 1% treatment failure, whichwas a significant reduction compared with no pharmacist inter-vention [19]. However, only one study examined mortality andfound no difference with pharmacist involvement [17].4 | Workflow4.1 | Time-Based OutcomesThe impact of pharmacist involvement in ED culture follow-upservices on time-based outcomes was evaluated across severalstudies [1, 8\u201311, 18\u201323, 26, 28, 32\u201334]. The two most evaluatedend points were time from culture result to first attempted pa-tient contact and time from culture result to initial review.4.1.1 | Time From Culture Result to First AttemptedPatient ContactFour studies evaluated the time from culture result to first at-tempted patient contact (Table 1) [8\u201310, 19]. Pharmacist involve-ment led to a reduction in the time from culture result to thefirst attempted patient contact across all studies reporting thisoutcome. Across these studies, the time from culture result tofirst attempted patient contact within the pharmacist groupranged from as little as 9.06 h [19] to 62.3 h [10]. Among the con-trol arms, the time ranged from 23.6 h [9] to 3 days [8].4.1.2 | Time From Culture Result to Initial ReviewThe time from culture result to initial review was also signifi-cantly shorter with pharmacist involvement across most studiesevaluating this end point [8, 10, 20, 21, 26, 28]. However, twostudies did not find a significant difference in time from cul-ture result to initial review [18, 22]. There were wide differencesacross studies, with the initial review occurring as soon as 0.8 hin the study by Brenneman and colleagues [26] and 47.9 h in thestudy by Shealy and colleagues [10].4.1.3 | Other Time-Based OutcomesOther time-based outcomes less frequently assessed included timefrom culture result to documentation, time to modification of anti-biotics, and time to completion of intervention. Mixed results wereseen when comparing these end points. The time from cultureresult to progress note charted/documentation was significantlyreduced in some studies [26, 28] but not in others [23]. Giruzzi andcolleagues reported a reduction in time to modification of antibi-otics from 6.79 days (interquartile range [IQR] 1.09\u20139.38) withouta pharmacist to 1.99 days (IQR 0.34\u20133.41) with one (p < 0.001) [20].The study by Dumkow and colleagues, which did not have a com-parison group, reported a median time of 2 days (IQR 2\u20133) for an-tibiotic modification [1]. The time to intervention completion wasevaluated in two studies, neither of which showed a significantdifference with or without pharmacist involvement [10, 32].A few studies assessed the time taken for staff to perform a cul-ture follow-up and/or time saved. Campo and colleagues reporteda median of 7 min (IQR 5\u201310) for performing a culture follow-upif requiring an action or 2 min (IQR 1\u20133) if not requiring an ac-tion [33]. Randolph and colleagues reported an average of 15 minfor a thorough review of a culture, noting that performing 200culture reviews per month would reduce ED physician aggregatemonthly workload by 50 h [11]. Grill and colleagues assessed pro-vider time saved by pharmacists engaging in culture follow-up[34]. Time savings were observed as follows: urine culture fol-low-up, 11.3 min per shift [standard error (SE) 1.05]; culture call-backs, 7.5 min per shift [SE 1.47]; other culture follow-up, 6.5 minper shift [SE 1.59]; patient call backs, 2.8 min per shift [1.04];blood culture follow-ups, 2.1 min per shift [SE 0.82] [34].4.2 | Types of Microbiological Data AssessedMost studies (n = 28) described culture follow-up services thatassessed positive cultures only (Table 1) [1\u201310, 12\u201321, 23\u201325, 27,29, 30, 32, 33]. Two studies specifically evaluated negative cul-ture follow-up services [24, 35]. One study assessed both posi-tive/negative culture types [30]. Nineteen studies assessed 3 ormore types of cultures [1\u20134, 6, 8, 11, 13, 15, 16, 18, 19, 21\u201323,29, 30, 32, 33]. The most common type of culture evaluatedwas urine cultures in 31/33 studies, followed by blood (n = 19),wound/tissue (n = 17), and sexually transmitted infections (STI)(n = 14). Ten culture follow-up services solely assessed urinecultures with or without STI tests or genital cultures. The leastcommonly reported tests evaluated included fungal cultures,Clostridioides difficile, and cerebrospinal fluid.4.3 | Professions Involved in Culture Follow-UpServicesAmong pharmacists described in culture-follow up services,22 studies specified the involvement of emergency medicinepharmacists [1, 2, 5\u201311, 13\u201318, 22, 24, 25, 27, 30\u201332]. Ten stud-ies described general pharmacist involvement without men-tion of a specialty [3, 4, 12, 19\u201321, 23, 28, 32, 33]. Pharmacyresidents were involved in some capacity in nine of the studies[5, 15, 18, 21, 26, 27, 30\u201332].Provider involvement in culture follow-up services consisted ofdoctors of medicine (MDs) (n = 11) [1, 4, 5, 7, 8, 15, 19, 22, 23, 27, 31],midlevel practitioners (n = 5) [2, 9, 19, 20, 29], and provider typenot specified (n = 12) [3, 6, 10, 13, 14, 16, 17, 24, 26, 28, 32, 33].Other professions described as participating in culture fol-low-up services among some studies included microbiology lab1056 Journal of the American College of Clinical Pharmacy, 2025personnel, an ED secretary, and assistant ED director, antimi-crobial stewardship and/or infectious disease pharmacists, andregistered nurses (RNs) [4, 5, 9, 13, 19, 24, 27, 29, 30, 32].4.4 | Pharmacist Tasks in Culture Follow-UpServicesThe most common tasks documented in the reviewed studies in-cluded reviewing culture results to determine the need for changeor modification in antibiotic therapy [1, 8\u201311, 15\u201317, 19\u201323, 25, 28\u201342]. Modifications mentioned in the literature included dose, dura-tion, and agent changes. Some workflows also included calling inor transmitting new prescriptions to community pharmacies, and/or fielding questions from community pharmacies [8, 9, 11, 21\u201323,28, 30, 32\u201334, 37, 38, 40, 41]. Other commonly mentioned inter-ventions included the discontinuation of unnecessary antibiotics[16, 19, 24, 30, 31, 35, 42]. Other interventions included forwardingresults to primary care providers, nursing homes, or outpatientspecialists [10, 33, 36, 38]. Pharmacists commonly provided pa-tient education about culture results and/or medication changes,instructing patients to return to the ED if necessary, and sendingpatient letters if unable to reach patients via telephone [8\u201311, 19,21\u201324, 26, 28, 33, 35, 37\u201339, 39\u201341].4.5 | Collaborative Practice Agreementsand CredentialingEight studies described the expanded scope of practice via eithercollaborative practice agreements or the privileging of pharmacystaff [9, 21, 23, 28, 33, 34, 40, 41]. Collaborative practice agreements(CPAs) are formal agreements between pharmacists and other pro-viders allowing for expanded services, such as making clinical in-terventions independently in culture follow-up services. Andradeand Grill described CPAs that included all culture types [21, 34].Within other institutions, the CPA was specific to certain culturetypes or infections, such as urinary tract infections (UTIs) orGroup A streptococcal pharyngitis (Table 2).Two studies described privileging of pharmacists, which is theprocess by which a health care organization authorizes an in-dividual to perform a specific activity within that organizationafter reviewing their credentials and performance [9, 23, 43].Pham and colleagues describe a pharmacist-led urine culturefollow-up protocol in which pharmacists were privileged to in-dependently adjust antimicrobial regimens [23]. Within Loborecand colleagues, ED specialty practice pharmacists (ED-SPPs)applied for both ambulatory and acute care privileges, alongwith an additional privilege to manage microbiologic test resultsfor patients discharged from the ED [9]. They mention that priv-ileged clinicians do not follow a protocol, but rather are granteda broader, \u201cauthentic scope expansion.\u201d [9].Cornell and colleagues describe a service utilizing clinicalpharmacist practitioners (CPP), which are pharmacists withadvanced practice licensure in the state of North Carolina [28].The CPP was able to prescribe antibiotics independently, withphysicians available for consultation if necessary. The studymentions that ID pharmacists created a reference document tohelp guide CPP antibiotic selection [28].Roels and colleagues sent an anonymous-response survey toED providers to gather opinions regarding the ED pharmacistTABLE 2 | Collaborative practice agreements and credentialing.Study State Process Types of cultures includedGrill 2019 [28] Michigan Collaborative practiceagreementAll includedRoels 2020 [30] Indiana Collaborative practiceagreementSymptomatic UTISkin/wound culturesSTIGroup A strep pharyngitisLoborec 2020 [25] Ohio Privileging All includedCampo 2021 [27] Florida Collaborative practiceagreementBacterial vaginosis (Gardnerella, Trichomonas),chlamydia/gonorrhea, Clostridioides difficileinfections, influenza, streptococcal pharyngitis, urinecultures, vaginal candidiasis, and wound culturesDietrich 2022 [31] Colorado Collaborative practiceagreementGroup A Streptococcus throatcultures and Vaginosis PanelsCornell 2022 [18] North Carolina Clinical PharmacistPractitioner (CPP)All includedPham 2023 [15] California Privileging UrineAndrade 2023 [13] New York Collaborative DrugTherapy Management(CDTM) protocolAll includedAbbreviations: CDTM: collaborative drug therapy management; CPP: clinical pharmacist practitioner; STI: sexually transmitted infection; UTI: urinary tractinfection.1057culture follow-up CPA [40]. Surveyed ED providers (n = 20) werecomfortable with the CPA process and supported the expansionof the CPA.5 | Discussion5.1 | Clinical OutcomesWithin this review, pharmacists in ED culture follow-up ser-vices played a significant role in increasing the appropriatenessof therapy, particularly in terms of guideline-directed ther-apy. This is evident from studies that reported significant im-provements in the appropriateness of antimicrobial regimenswhen pharmacists were involved [27, 29]. Pharmacist involve-ment led to fewer missed interventions as well [18, 26, 28, 32].However, the impact on readmission and ED revisit rates wasmixed. While some studies reported significant reductions inthese rates, others found no difference. This variability sug-gests a need for more studies with standardized definitions andconsistent methodologies to draw more definitive conclusions.Additionally, the limited number of studies assessing mortality(n = 1) and treatment failure (n = 1) indicates a gap in the litera-ture that future research should address.Few studies assessed culture follow-up services in whichnegative cultures were evaluated, which represents a poten-tial untapped area for antimicrobial stewardship initiatives.Nonetheless, several studies evaluated antibiotic discontinua-tion rates even in the setting of positive cultures. For instance,positive urine cultures in the absence of urinary symptomslikely represent asymptomatic bacteriuria, in which antibiotictreatment is not recommended [44]. With pharmacist involve-ment, antibiotic discontinuation occurred more often [24, 30].Zhang and colleagues documented 29% of antibiotic days weresaved by pharmacist intervention, and Rainess and colleaguesnoted avoidance of 280 antibiotic days by pharmacist interven-tion [25, 31]. It is recommended that antimicrobial stewardshipinitiatives focus on reducing antibiotic prescribing for antibiotic-inappropriate conditions [45]. Pharmacist involvement in EDculture follow-up services significantly reduced unnecessaryantibiotic exposure, which has broad implications for antimi-crobial stewardship programs. Further expansion of culture fol-low-up services to include both positive and negative culturescould have significant impacts on deprescribing and antimicro-bial stewardship.5.2 | WorkflowWide variability was found in terms of personnel involvement,types/credentialing of pharmacists, types of cultures reviewed,and timing of interventions. Pharmacist involvement signifi-cantly reduced the time to various culture follow-up actionscompared with services without pharmacist involvement. Thisincludes reductions in the time from culture result to first at-tempted patient contact and initial review. However, widelyvariable intervention times were noted across studies. Timeto initial review occurred as fast as 0.8 h and as long as 3 days[18, 26]. Time to first patient contact ranged from 9.06 to 62.3 h[10, 19]. The variability in time reductions across studies may bedue to several possible confounding variables. Different person-nel were involved in the culture follow-up services, specificallywithin the pre-implementation arms of studies. For instance,studies that did not find a significant time difference after in-volvement of a pharmacist often had highly skilled nurse leadersor other efficient pre-existing processes [18]. This raises an im-portant question: to what extent are improvements attributableto pharmacist expertise versus the effect of re-training or pro-tocol optimization among existing staff? Future studies shouldexplore whether structured re-education or updated workflowsfor non-pharmacist personnel could yield similar benefits, andhow these approaches compare with pharmacist-led models interms of clinical and operational outcomes. Yet other studieswere faced with a significantly higher proportion of patients inthe post-implementation group who were not able to be reachedafter several telephone attempts, which could have impactedboth time-based and clinical findings [10]. Other possible ex-planations for differences in time-based outcomes include vari-ability in how pharmacists were alerted to culture data. Somestudies reported real-time alerts to new culture data [9, 10],while others relied on print-outs of culture data once per day[22, 32], which might explain their inability to detect a differencein time-based outcomes. Rapid diagnostic testing is yet anothervariable that likely impacted variability in time-based outcomesacross studies, as demonstrated by Brenneman and colleagues,who utilized the Verigene platform for blood cultures (LuminexCorporation, Austin, TX) [26].The presence of collaborative practice agreements (CPA) orpharmacist privileging could further streamline workflows byeliminating the need for secondary reviews by other providersfor certain patient types. There was significant variability inthe structure and scope of CPAs, with some allowing pharma-cist oversight of all culture types [21, 34] and others restrictingoversight to certain cultures, such as urine or group A strepto-coccal pharyngitis. Still other studies described advanced phar-macy practitioners or privileging of pharmacists, options, whichwould not be available in all states depending on laws and regu-lations. One study assessed outcomes before and after privileg-ing pharmacists; finding reduced median time to patient contact(14.9 h [standard deviation (SD) 2.5\u201327.9] vs. 23.6 h [SD 12.4\u201393],p = 0.0023) [9]. Studies comparing workflow and clinical impactof ED culture follow-up services with and without CPAs or priv-ileging are lacking.Many studies did not specify which personnel were engagedin specific sub-tasks within culture follow-up services, suchas calling patients, calling in new prescriptions, faxing results,etc. The ideal team make-up for performing culture follow-ups remains unknown. Greater specificity describing teamconstructs and how team structure influences workflow andoutcomes is needed. Ideally, future studies will apply implemen-tation science frameworks such as the Exploration, Preparation,Implementation, Sustainment (EPIS) framework to culture fol-low-up services [46].While most studies focused on clinical and operational out-comes, cost implications were rarely addressed. One study byDietrich and colleagues provided a cost analysis, estimating acost avoidance of $1,665,063.06 across 10,894 ED outpatient cul-ture review interventions [41]. This suggests that pharmacist-led1058 Journal of the American College of Clinical Pharmacy, 2025interventions may offer substantial economic value; though fur-ther research is needed to validate and generalize these findings.5.3 | Implications for PracticeThis review underscores the valuable role pharmacists can playin ED culture follow-up services, particularly in improving theappropriateness of antimicrobial therapy and reducing timeto follow-up actions. These findings support the integration ofpharmacists into ED workflows as a strategy to enhance antimi-crobial stewardship and optimize patient outcomes. Institutionsmay consider expanding pharmacist responsibilities throughcollaborative practice agreements or privileging to streamlineinterventions and reduce provider workload. Additionally, thedemonstrated time savings and improved intervention appropri-ateness suggest that pharmacist-led models could contribute tomore efficient ED operations. These insights can inform hospi-tal policies, staffing models, and the design of future interven-tions aimed at improving transitional care in the ED setting.5.4 | Strengths and LimitationsThis systematic review has several strengths, including a thor-ough search strategy, the use of quality assessment tools, and aninterdisciplinary author team that helped reduce bias. However,there are also limitations to consider. The heterogeneity in out-come definitions, such as varying time frames for readmission/ED revisit and differences in baseline rates before pharmacistinvolvement, hinders direct comparisons across studies. Not allED revisits and/or readmissions assessed were attributable tothe index infection. Additionally, the variability in personnel in-volved in culture follow-up services makes it challenging to drawconclusions about the optimal workflow or team composition.5.5 | Future DirectionsFuture research should focus on expanding culture follow-upprograms to include negative cultures and deprescribing efforts.There is also a need for studies that explore the impact of phar-macy services through CPA/credentialing and ways to furtherimprove the efficiency of culture follow-up services. Addressingthese gaps will provide a more comprehensive understanding ofthe benefits and challenges associated with pharmacist involve-ment in ED culture follow-up services.6 | ConclusionIn conclusion, the involvement of pharmacists in ED culturefollow-up services demonstrates clear benefits in terms of reduc-ing the time to initial review and patient contact. While the im-pact on readmission and ED revisit rates is mixed, the evidencesuggests potential improvements in these areas. This reviewhighlights the need for further studies to explore the benefitsof negative culture follow-up services, expanded pharmacy ser-vices through collaborative practice agreements (CPA) and cre-dentialing, and strategies to enhance the efficiency of culturefollow-up services. Addressing these gaps will provide a morecomprehensive understanding of the role of pharmacists in EDculture follow-up services and their contribution to improvingclinical outcomes and workflow efficiency.Author ContributionsElizabeth W. Covington: conceptualization, investigation, writing \u2013original draft, methodology, writing \u2013 review and editing, project admin-istration, data curation, supervision, resources. Adelia Grabowsky:investigation, writing \u2013 original draft, methodology, validation, writing\u2013 review and editing, software, formal analysis, resources, data cura-tion. Michal Moore: conceptualization, writing \u2013 original draft, datacuration, writing \u2013 review and editing. Adrianna T. Reagan: inves-tigation, writing \u2013 original draft, data curation, writing \u2013 review andediting. Leborah Lee: validation, writing \u2013 review and editing. RachelCody: writing \u2013 original draft, writing \u2013 review and editing.Conflicts of InterestThe authors declare no conflicts of interest.Data Availability StatementData sharing is not applicable to this article as no new data were createdor analyzed in this study.References1. L. E. Dumkow, R. M. Kenney, N. C. MacDonald, J. J. Carreno, M. K.Malhotra, and S. L. Davis, \u201cImpact of a Multidisciplinary Culture Fol-low-Up Program of Antimicrobial Therapy in the Emergency Depart-ment,\u201d Infectious Diseases and Therapy 3, no. 1 (2014): 45\u201353, https://doi.org/10.1007/s40121-014-0026-x.2. J. S. Mikhaeil, H. Jalali, A. Orchanian- Cheff, and L. B. Chartier,\u201cQuality Assurance Processes Ensuring Appropriate Follow-Up of TestResults Pending at Discharge in Emergency Departments: A System-atic Review,\u201d Annals of Emergency Medicine 76, no. 5 (2020): 659\u2013674,https://doi.org/10.1016/j.annemergmed.2020.07.024.3. P. Burchett, S. Harpin, A. Petersen- Smith, and K. Emery, \u201cImprovinga Urine Culture Callback Follow-Up System in a Pediatric EmergencyDepartment,\u201d Journal of Pediatric Health Care 29, no. 6 (2015): 518\u2013525,https://doi.org/10.1016/j.pedhc.2015.06.003.4. T. Schoffelen, C. Papan, E. Carrara, et al., \u201cEuropean Society of Clin-ical Microbiology and Infectious Diseases Guidelines for AntimicrobialStewardship in Emergency Departments (Endorsed by European Asso-ciation of Hospital Pharmacists),\u201d Clinical Microbiology and Infection30, no. 11 (2024): 1384\u20131407, https://doi.org/10.1016/j.cmi.2024.05.014.5. M. J. Ortmann, E. G. Johnson, D. H. Jarrell, et al., \u201cASHP Guidelineson Emergency Medicine Pharmacist Services,\u201d American Journal ofHealth-System Pharmacy 78, no. 3 (2021): 261\u2013275, https://doi.org/10.1093/ajhp/zxaa378.6. B. M. Farmer, B. D. Hayes, R. Rao, N. Farrell, and L. Nelson, \u201cTheRole of Clinical Pharmacists in the Emergency Department,\u201d Journalof Medical Toxicology 14, no. 1 (2018): 114\u2013116, https://doi.org/10.1007/s13181-017-0634-4.7. American College of Emergency Physicians Policy Statements,\u201cClinical Pharmacist Services in the Emergency Department,\u201d Annalsof Emergency Medicine 77, no. 6 (2021): e127\u2013e133, https://doi.org/10.1016/j.annemergmed.2021.03.009.8. S. N. Baker, N. M. Acquisto, E. D. Ashley, R. J. Fairbanks, S. E. Beam-ish, and C. E. Haas, \u201cPharmacist-Managed Antimicrobial StewardshipProgram for Patients Discharged From the Emergency Department,\u201dJournal of Pharmacy Practice 25, no. 2 (2012): 190\u2013194, https://doi.org/10.1177/0897190011420160.10599. S. M. Loborec, J. A. Bazan, N. V. Brown, M. B. Shirk, and T. A. Jor-dan, \u201cPrivileging Pharmacists Improves Time to Patient Notification inthe Microbiological Test Review Process for Patients Discharged Fromthe Emergency Department,\u201d American Journal of Health-System Phar-macy 77, no. Supplement_1 (2020): S19\u2013S24, https://doi.org/10.1093/ajhp/zxz335.10. S. C. Shealy, C. Alexander, T. G. Hardison, et al., \u201cPharmacist-Driven Culture and Sexually Transmitted Infection Testing Follow-UpProgram in the Emergency Department,\u201d Pharmacy 8, no. 2 (2020): 72,https://doi.org/10.3390/pharmacy8020072 .11. T. C. Randolph, A. Parker, L. Meyer, and R. Zeina, \u201cEffect of aPharmacist-Managed Culture Review Process on Antimicrobial Ther-apy in an Emergency Department,\u201d American Journal of Health-SystemPharmacy 68, no. 10 (2011): 916\u2013919, https://doi.org/10.2146/ajhp090552 .12. M. J. Page, J. E. McKenzie, P. M. Bossuyt, et al., \u201cThe PRISMA 2020Statement: An Updated Guideline for Reporting Systematic Reviews,\u201dSystematic Reviews 10, no. 1 (2021): 89, https://doi.org/10.1186/s13643-021-01626 -4.13. Covidence Systematic Review Software, Veritas Health Innovation,Melbourne, Australia, www.covidence.org.14. Ottawa Hospital Research Institute. accessed February 14, 2016,https://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.15. Y. Zhao, N. Stornelli, K. McAllister, L. McDaniel, and J. Schad,\u201cEvaluating the Impact of Emergency Department Clinical PharmacistIntegration Within a Discharge Urine Culture Follow-Up Program,\u201dJournal of the American College of Clinical Pharmacy 6, no. 9 (2023):1008\u20131014, https://doi.org/10.1002/jac5.1853.16. A. Richardson, S. Muhammad, C. McSwain, and H. Tran, \u201cImpactof Pharmacist Involvement in Post-Discharge Emergency DepartmentCulture Review,\u201d Hospital Pharmacy 59 (2024): 584\u2013587, https://doi.org/10.1177/00185787241238309.17. C. D. Waters, B. J. Bitton, A. Torosyan, and K. P. Myers, \u201cClinicalPharmacist Management of Bacteremia in a Community HospitalEmergency Department,\u201d Annals of Pharmacotherapy 51, no. 6 (2017):465\u2013472, https://doi.org/10.1177/1060028016688226.18. R. D. Santiago, J. A. Bazan, N. V. Brown, E. J. Adkins, and M. B.Shirk, \u201cEvaluation of Pharmacist Impact on Culture Review Process forPatients Discharged From the Emergency Department,\u201d Hospital Phar-macy 51, no. 9 (2016): 738\u2013743, https://doi.org/10.1310/hpj5109-738.19. A. Olson, J. Feih, R. Feldman, C. Dang, and M. Stanton, \u201cInvolvementof Pharmacist-Reviewed Urine Cultures and Sexually Transmitted In-fections in the Emergency Department Reduces Time to AntimicrobialOptimization,\u201d American Journal of Health-System Pharmacy 77, no.Supplement_2 (2020): S54\u2013S58, https://doi.org/10.1093/ajhp/zxaa064.20. M. E. Giruzzi, J. C. Tawwater, and J. L. Grelle, \u201cEvaluation of Anti-biotic Utilization in an Emergency Department After Implementationof an Antimicrobial Stewardship Pharmacist Culture Review Service,\u201dHospital Pharmacy 55, no. 4 (2020): 261\u2013267, https://doi.org/10.1177/0018578719844171.21. J. Andrade, J. Truong, and C. Ciaramella, \u201cExpansion of aPharmacist-Led Culture Follow-Up Program to Real-Time Notificationof Multidrug-Resistant Microbiology Results in the Emergency Depart-ment,\u201d Hospital Pharmacy 58, no. 4 (2023): 368\u2013375, https://doi.org/10.1177/00185787231155833.22. A. Boot, A. S. Weideling, A. Wilson, D. Burnham, and S. P. Ward,\u201cImpact of a Pharmacy-Driven Culture Callback Protocol on Antimi-crobial Therapy Optimization in the Emergency Department,\u201d Journalof the American Pharmacists Association 64 (2024): 102072, https://doi.org/10.1016/j.japh.2024.102072.23. D. Pham, S. Lee, S. Abrishami, B. Chakravarthy, and S. Saadat,\u201cUtilization and Impact of Pharmacist-Led, Urinary Culture Follow-UpAfter Discharge From the Emergency Department,\u201d Western Journal ofEmergency Medicine 24, no. 3 (2023): 396\u2013400, https://doi.org/10.5811/westjem.59116.24. B. Kofoed, J. Morris, and J. Rich, \u201cAn Initiative to Stop AntibioticsPrescribed for Urinary Symptoms When Urine Culture Is Negative,\u201dJournal for Healthcare Quality: Official Publication of the National Asso-ciation for Healthcare Quality 45, no. 6 (2023): 371\u2013376, https://doi.org/10.1097/JHQ.00000 00000 000403.25. R. A. Rainess, V. V. Patel, J. B. Cavanaugh, and J. Hill, \u201cEvaluatingthe Addition of a Clinical Pharmacist Service to a Midlevel Provider-Driven Culture Follow-Up Program in a Community Emergency De-partment,\u201d Journal of Pharmacy Technology 37, no. 3 (2021): 140\u2013146,https://doi.org/10.1177/87551225211000363.26. R. Brenneman, M. B. Shirk, C. Liscynesky, N. Tran, and E. Rozy-cki, \u201cPharmacist Involvement in Blood Culture Follow Up for PatientsDischarged From the Emergency Department,\u201d American Journal ofEmergency Medicine 72 (2023): 101\u2013106, https://doi.org/10.1016/j.ajem.2023.07.019.27. A. S. Almulhim, A. Aldayyen, K. Yenina, A. Chiappini, and T. M.Khan, \u201cOptimization of Antibiotic Selection in the Emergency De-partment for Urine Culture Follow Ups, a Retrospective Pre-PostIntervention Study: Clinical Pharmacist Efforts,\u201d Journal of Pharma-ceutical Policy and Practice 12 (2019): 8, https://doi.org/10.1186/s40545-019-0168-z.28. W. K. Cornell, G. Hile, T. Stone, J. Hannum, M. Reichert, and M.K. Hollinger, \u201cImpact of Advanced Practice Pharmacists on a CultureResponse Program in the Emergency Department,\u201d American Journalof Health-System Pharmacy 79, no. Suppl 4 (2022): S106\u2013S114, https://doi.org/10.1093/ajhp/zxac157.29. K. Miller, M. A. McGraw, A. Tomsey, et al., \u201cPharmacist Additionto the Post-ED Visit Review of Discharge Antimicrobial Regimens,\u201dAmerican Journal of Emergency Medicine 32, no. 10 (2014): 1270\u20131274,https://doi.org/10.1016/j.ajem.2014.07.033.30. M. Benson, M. Dewey, and D. Friesner, \u201cPharmacist-Led UrineCulture Follow-Ups in a Rural Emergency Department,\u201d Journal of theAmerican Pharmacists Association: JAPhA 63, no. 4S (2023): S39\u2013S42,https://doi.org/10.1016/j.japh.2022.08.019.31. X. Zhang, N. Rowan, B. M. Pflugeisen, and S. Alajbegovic, \u201cUrineCulture Guided Antibiotic Interventions: A Pharmacist Driven Antimi-crobial Stewardship Effort in the ED,\u201d American Journal of EmergencyMedicine 35, no. 4 (2017): 594\u2013598, https://doi.org/10.1016/j.ajem.2016.12.036.32. L. C. Davis, R. B. Covey, J. S. Weston, B. B. Y. Hu, and G. A. Laine,\u201cPharmacist-Driven Antimicrobial Optimization in the EmergencyDepartment,\u201d American Journal of Health-System Pharmacy 73, no. 5Suppl 1 (2016): S49\u2013S56, https://doi.org/10.2146/sp150036.33. M. Campo, K. E. Samai, J. E. Dean, and J. A. Lund, \u201cImpact of In-corporating Pharmacy Residents Into a Pharmacist-Managed CultureReview Service During Weekend Staffing Commitments,\u201d Journal ofPharmacy Practice 34, no. 2 (2021): 247\u2013252, https://doi.org/10.1177/0897190019867489.34. J. Grill, C. Bryant, K. Markel, and S. J. Wisniewski, \u201cA Study of TimeSaved by Emergency Medicine Physicians Through Working With Clin-ical Pharmacists in the Emergency Department,\u201d American Journalof Emergency Medicine 37, no. 9 (2019): 1720\u20131722, https://doi.org/10.1016/j.ajem.2018.12.028.35. Y. Wang, K. Knobloch, S. Lovett, N. Lyons, and M. A. Rech, \u201cAPharmacist-Driven Deprescribing Protocol for Negative Urine and Sex-ually Transmitted Infection Cultures in the Emergency DepartmentIncreases Antibiotic-Free Days,\u201d American Journal of Health-SystemPharmacy: AJHP: Official Journal of the American Society of Health-System Pharmacists 81, no. 3 (2024): e83\u2013e89, https://doi.org/10.1093/ajhp/zxad255.1060 Journal of the American College of Clinical Pharmacy, 202536. E. A. Van Devender, \u201cOptimizing Antimicrobial Therapy Througha Pharmacist-Managed Culture Review Process in the ED,\u201d AmericanJournal of Emergency Medicine 32, no. 9 (2014): 1138, https://doi.org/10.1016/j.ajem.2014.05.037.37. E. Lingenfelter, Z. Drapkin, K. Fritz, S. Youngquist, T. Madsen, andM. Fix, \u201cED Pharmacist Monitoring of Provider Antibiotic SelectionAids Appropriate Treatment for Outpatient UTI,\u201d American Journalof Emergency Medicine 34, no. 8 (2016): 1600\u20131603, https://doi.org/10.1016/j.ajem.2016.05.076.38. J. Y. Wu, R. Balmat, M. L. Kahle, et al., \u201cEvaluation of a HealthSystem-Wide Pharmacist-Driven Emergency Department LaboratoryFollow-Up and Antimicrobial Management Program,\u201d American Jour-nal of Emergency Medicine 38, no. 12 (2020): 2591\u20132595, https://doi.org/10.1016/j.ajem.2019.12.052.39. J. Tweedle, E. Mercado, N. Truesdale, D. Leonard, and J. A. O. Nesi-ama, \u201cDecreasing Review and Notification Times of Genital and UrineCultures in a Pediatric Emergency Department: An Observational Be-fore and After Study,\u201d Journal of the American College of Emergency Phy-sicians Open 1, no. 6 (2020): 1512\u20131519, https://doi.org/10.1002/emp2.12189.40. C. Roels, E. Pavich, B. McCrate, R. Adams, and T. Hrisomalos, \u201cIm-plementing a Pharmacist-Led Emergency Department MicrobiologyFollow-Up Collaborative Practice Agreement,\u201d Journal of the AmericanPharmacists Association: JAPhA 60, no. 5 (2020): e64\u2013e69, https://doi.org/10.1016/j.japh.2020.03.007.41. S. K. Dietrich, B. T. Bushong, E. A. Schneider-Smith, and M. A.Mixon, \u201cEmergency Medicine Pharmacist Interventions Reducing Ex-posure to Costs (EMPIRE- C),\u201d American Journal of Emergency Medi-cine 54 (2022): 178\u2013183, https://doi.org/10.1016/j.ajem.2022.01.054.42. H. Bao, Y. Dubrovskaya, S. P. Jen, et al., \u201cNovel MultidisciplinaryApproach for Outpatient Antimicrobial Stewardship Using an Emer-gency Department Follow-Up Program,\u201d Journal of Pharmacy Practice36, no. 2 (2023): 329\u2013335, https://doi.org/10.1177/08971900211048311.43. T. A. Jordan, J. A. Hennenfent, J. J. Lewin, III, T. W. Nesbit, andR. Weber, \u201cElevating Pharmacists' Scope of Practice Through a Health-System Clinical Privileging Process,\u201d American Journal of Health-System Pharmacy 73, no. 18 (2016): 1395\u20131405, https://doi.org/10.2146/ajhp150820.44. L. E. Nicolle, K. Gupta, S. F. Bradley, et al., \u201cClinical Practice Guide-line for the Management of Asymptomatic Bacteriuria: 2019 Update bythe Infectious Diseases Society of America,\u201d Clinical Infectious Diseases68, no. 10 (2019): e83\u2013e110, https://doi.org/10.1093/cid/ciy1121.45. J. B. Ladines-Lim, M. A. Fischer, J. A. Linder, and K. P. Chua, \u201cAp-propriateness of Antibiotic Prescribing in US Emergency DepartmentVisits, 2016\u20132021,\u201d Antimicrobial Stewardship and Healthcare Epidemi-ology 4, no. 1 (2024): e79, https://doi.org/10.1017/ash.2024.79.46. E. A. McGuier, D. J. Kolko, N. A. Stadnick, et al., \u201cAdvancing Re-search on Teams and Team Effectiveness in Implementation Science:An Application of the Exploration, Preparation, Implementation, Sus-tainment (EPIS) Framework,\u201d Implementation Research and Practice4 (2023): 26334895231190855, https://doi.org/10.1177/26334 895231190855.Supporting InformationAdditional supporting information can be found online in theSupporting Information section. Data S1: jac570106-sup- 0001-supinfo.pd // I'm trying to study this paper. please help me interpret the data to prepare for class. i need to know the whole thing, but my assigned section is about collaborative practice agreements."
    },
    {
      "role": "assistant",
      "content": "Of course! Let's break down this systematic review on pharmacist-led culture follow-up services in the emergency department (ED), with a special focus on your assigned section about Collaborative Practice Agreements (CPAs).\n\nHere is your study guide.\n\n***\n\n### **Global Summary**\n\nThis systematic review evaluates the impact of integrating pharmacists into Emergency Department (ED) culture follow-up services. These services involve reviewing microbiology results (e.g., blood, urine, wound cultures) for patients who have been discharged from the ED and ensuring appropriate antimicrobial therapy. The analysis of multiple studies shows that pharmacist involvement consistently and significantly improves workflow efficiency, drastically reducing the time from culture result availability to initial review and first patient contact. Clinically, pharmacists demonstrably increase the appropriateness of antimicrobial regimens, reduce unnecessary antibiotic days (a key antimicrobial stewardship metric), and improve guideline adherence. However, the impact on hard clinical outcomes like ED revisit and hospital readmission rates is mixed. The review identifies Collaborative Practice Agreements (CPAs) and pharmacist privileging as powerful enablers that allow pharmacists to operate at the top of their license, further streamlining these interventions and reducing dependency on other providers for authorization.\n\n### **Key Concepts**\n\n*   **Core Function:** ED culture follow-up services are a form of transitional care and antimicrobial stewardship aimed at patients discharged from the ED with pending culture results. The goal is to ensure timely and appropriate action based on those results.\n*   **Workflow Impact:** Pharmacist involvement consistently leads to faster time-to-intervention metrics, including time to initial culture review and time to first patient contact, compared to models led by other professionals.\n*   **Clinical and Stewardship Impact:** Pharmacists improve the appropriateness of antibiotic therapy, increase adherence to guidelines, and are particularly effective at discontinuing unnecessary antibiotics (e.g., for asymptomatic bacteriuria).\n*   **Collaborative Practice Agreements (CPAs):**\n    *   A CPA is a formal, written agreement between a pharmacist and a physician/institution that authorizes the pharmacist to perform specific patient care functions, such as independently modifying or initiating drug therapy based on culture results.\n    *   CPAs eliminate the need for a pharmacist to contact a physician for approval on every intervention, drastically improving efficiency.\n    *   The scope of CPAs can vary widely\u2014some are comprehensive (covering all culture types), while others are disease-specific (e.g., only for UTIs or strep pharyngitis).\n*   **Privileging & Advanced Practice:** Some institutions use \"privileging\" or advanced practice designations (like Clinical Pharmacist Practitioners) to grant pharmacists similar autonomous responsibilities. This is often described as a broader \"scope expansion\" beyond a strict protocol.\n*   **Provider Reception:** The limited data available (from one survey) indicates that ED providers are generally comfortable with and supportive of pharmacists operating under CPAs for this function.\n\n### **Quiz**\n\n1.  **According to the review, what is the primary mechanism by which Collaborative Practice Agreements (CPAs) enhance pharmacist-led culture follow-up services?**\n    A. They allow pharmacists to work from home.\n    B. They mandate higher salaries for clinical pharmacists.\n    C. They authorize pharmacists to independently perform specific clinical interventions, such as modifying antibiotic therapy.\n    D. They require all culture results to be reviewed by an infectious disease physician first.\n    E. They shift the responsibility for culture follow-up entirely to nursing staff.\n\n2.  **The systematic review notes variability in the scope of CPAs. Which of the following best describes this variability?**\n    A. All CPAs described were limited to reviewing blood cultures only.\n    B. Some CPAs were comprehensive, while others were restricted to specific infections or culture types.\n    C. CPAs were only implemented in pediatric emergency departments.\n    D. The variability was solely based on the pharmacist's years of experience.\n    E. CPAs universally prohibited pharmacists from calling patients directly.\n\n3.  **A key finding regarding the impact of CPAs and privileging on workflow was:**\n    A. They had no effect on the time it took to review cultures.\n    B. They increased the administrative burden on physicians.\n    C. They were associated with a significant reduction in the time to patient notification and contact.\n    D. They resulted in a higher rate of missed interventions.\n    E. They were only feasible in large, academic medical centers.\n\n### **Answer Key and Rationales**\n\n1.  **Correct Answer: C.** They authorize pharmacists to independently perform specific clinical interventions, such as modifying antibiotic therapy.\n    *   **Rationale:** This is the fundamental purpose of a CPA in this context. It delegates authority from a physician to a pharmacist, allowing the pharmacist to manage therapy according to a pre-established protocol or agreement without needing individual cosignature or approval for each case, which streamlines the process.\n\n2.  **Correct Answer: B.** Some CPAs were comprehensive, while others were restricted to specific infections or culture types.\n    *   **Rationale:** The paper provides examples from Table 2 and the text, showing that while some institutions (e.g., Michigan, Ohio) implemented CPAs for \"all\" culture types, others (e.g., Indiana, Florida) had agreements specific to UTIs, STIs, or strep pharyngitis. This highlights that CPA structure is not one-size-fits-all.\n\n3.  **Correct Answer: C.** They were associated with a significant reduction in the time to patient notification and contact.\n    *   **Rationale:** The discussion section directly states that the presence of CPAs or privileging could \"further streamline workflows.\" It cites Loborec 2020, which found a reduced median time to patient contact after privileging pharmacists. This is a logical outcome of removing the procedural bottleneck of requiring secondary provider approval.\n\n### **Suggested Further Reading**\n\n1.  **Ortmann MJ, Johnson EG, Jarrell DH, et al. ASHP Guidelines on Emergency Medicine Pharmacist Services.** *Am J Health Syst Pharm.* 2021;78(3):261-275. doi:10.1093/ajhp/zxaa378\n    *   **Why:** These are the formal guidelines from the American Society of Health-System Pharmacists. They provide a comprehensive overview of the recommended roles and responsibilities of EM pharmacists, which heavily informs the development and implementation of services like culture follow-up and the use of CPAs.\n\n2.  **Farmer BM, Hayes BD, Rao R, Farrell N, Nelson LS. The Role of Clinical Pharmacists in the Emergency Department.** *J Med Toxicol.* 2018;14(1):114-116. doi:10.1007/s13181-017-0634-4\n    *   **Why:** This concise review offers an excellent, high-level summary of the diverse roles EM pharmacists play, placing specialized services like culture follow-up within the broader context of ED pharmacy practice. It's a great primer on the value proposition of the specialty.\n\n***\n*For learning purposes only; not medical advice.*"
    },
    {
      "role": "user",
      "content": "help me decide if my hospital should implement culture follow up for blood cultures only or for all cultures"
    }
  ],
  "rubrics": [
    "The response should include a concise 150-250-word summary for a decision to implement culture follow-up.",
    "The response should provide a bullet list of at least 4-5 key concepts for the prompt question \"help me decide if my hospital should implement culture follow-up for blood cultures only or for all cultures\".  For example, Blood Culture-Specific Values, Stewardship Opportunities with All Cultures, Workflow and Efficiency, Resource Allocation, and Clinical Outcomes.",
    "The response should provide 3-5 multiple-choice questions that include an Answer Key and Rationale Section.",
    "The response should provide 1-2 high-quality suggestions for further reading, for example, landmark trials, guidelines, or systematic reviews.",
    "The response should include full citation details for each suggested further reading. For example, author, date, title, source information, and DOI.",
    "The response should use technical language appropriate for various types of medical students. For example, medical students, pharmacy students, DO (Doctor of Osteopathic Medicine), and other health professional students.",
    "The response should conclude with a disclaimer at the end. For example, \"For learning purposes only; not medical advice.\"",
    "The response should order section labels as follows: Summary, Key Concepts, Multiple Choice Questions, Answer Key and Rationales, and Suggested Further Reading.",
    "The response should label 5 multiple-choice options for each question, for example, A-E.",
    "The response should state the pros and cons of blood culture follow-up services vs. comprehensive service for all culture types. For example, resource allowance, clinical decision relevance, and workload.",
    "The response should present a side-by-side comparison of benefits and risks for implementing culture follow-up for blood cultures only versus for all cultures. For example, list 3\u20135 specific benefits and 3\u20135 specific risks for each option (e.g., improved sepsis detection vs increased lab workload).",
    "The response should identify and describe the operational/resource implications for each option. For example, expected laboratory workload changes, staffing (FTE) needs, IT/notification requirements.",
    "The response should give a phased plan example for a culture follow-up service for all culture types. For example, starting with blood cultures with a goal of rapid expansion to include multiple culture types. For example, urine, wound, and STI cultures.",
    "The response should provide an answer key and a brief (1\u20132 sentence) rationale for each multiple-choice question."
  ],
  "metadata": {
    "task_id": "c26ad9cc-b82a-49b3-8db6-12e3c97c0cda",
    "context_id": "1768864c-8ec4-43cd-89a7-8bff6b2c1823",
    "context_category": "Domain Knowledge Reasoning",
    "sub_category": "Healthcare"
  }
}